The impact of obesity on prostate cancer recurrence observed after exclusion of diabetics

Cancer Causes and Control

Volumn 26, Issue 6, 2015, Pages 821-830

  Agalliu, Ilir ^a   Williams, Steve ^a   Adler, Brandon ^a   Androga, Lagu ^a   Siev, Michael ^a   Lin, Juan ^a   Xue, Xiaonan ^a   Huang, Gloria ^a   Strickler, Howard D ^a   Ghavamian, Reza ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes; Insulin signaling; Obesity; Prostate cancer; Recurrence

Indexed keywords

INSULIN; SOMATOMEDIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; CANCER GRADING; CANCER RECURRENCE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTRONIC MEDICAL RECORD; ETHNICITY; GLEASON SCORE; HISPANIC; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; ROBOTIC ASSISTED LAPAROSCOPIC PROSTATECTOMY; SIGNAL TRANSDUCTION; AGED; BLOOD; COMPLICATION; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR RECURRENCE;

AGED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OBESITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84929706609     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-015-0554-z     Document Type: Article

References (48)

1. American Cancer Society (ACS) (2014) Cancer facts & figures 2014. Atlanta, GA
2. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S et al (2014) SEER cancer statistics review, 1975–2011. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2011/. Based on November 2013 SEER data submission, posted to the SEER web site, April 2014
3. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29
4. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M et al (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78–85
5. Carter HB, Piantadosi S, Isaacs JT (1990) Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 143(4):742–746
6. MacInnis RJ, English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17(8):989–1003
7. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW et al (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev 15(10):1977–1983
8. Hsing AW, Sakoda LC, Chua S Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86(3):s843–s857
9. Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29:88–97
10. Cao Y, Ma J (2011) Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res 4(4):486–501
11. Chalfin HJ, Lee SB, Jeong BC, Freedland SJ, Feng Z, Trock BJ et al (2014) Obesity and long-term survival after radical prostatectomy. J Urol 192(4):1100–4. doi:10.1016/j.juro.2014.04.086
12. Hu MB, Xu H, Bai PD, Jiang HW, Ding Q (2014) Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose–response meta-analysis of 36,927 patients. Med Oncol 31(2):829
13. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915–928
14. Renehan AG, Frystyk J, Flyvbjerg A (2006) Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 17(8):328–336
15. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J et al (2008) A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomark Prev 17:921–929
16. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE et al (2009) Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101(1):48–60
17. Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomark Prev 15(11):2056–2062
18. Zhang F, Yang Y, Skrip L, Hu D, Wang Y, Wong C et al (2012) Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetol 49(Suppl 1):S235–S246
19. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35(2):299–304
20. Oh JJ, Hong SK, Lee S, Sohn SJ, Lee SE (2013) Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy. Int Urol Nephrol 45(1):121–127
21. Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI et al (2014) Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol 32(4):999–1005. doi:10.1007/s00345-013-1171-7
22. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364–1379
23. American Diabetes Association (2014) Standards of medical care in diabetes—2014. Diabetes Care 37(Suppl 1):S14–S80
24. Ligibel JA, Strickler HD (2013) Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions. Am Soc Clin Oncol Educ Book. 2013:52-9. doi:10.1200/EdBook_AM.2013.33.52
25. Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc B 34:187–220
26. Hosmer DW, Lemeshow S (1999) Applied survival analysis. Wiley, New York
27. Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303(3):235–241
28. Ogden CL, Carrol MD, Kit BK, Flegal KM (2012) Prevalence of obesity in the United States, 2009–2010. In: National Center for Health Statistics (NCHS) Data Brief 2012, vol 82, pp 1–7
29. Wong RJ, Chou C, Ahmed A (2014) Long Term Trends and Racial/Ethnic Disparities in the Prevalence of Obesity. J Community Health 39(6):1150–1160
30. Asmar R, Beebe-Dimmer JL, Korgavkar K, Keele GR, Cooney KA (2013) Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 16(1):62–66
31. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ et al (2005) Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology 66(5):1060–1065
32. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039–1047
33. Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K, Virtamo J (2009) Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 101(18):1272–1279
34. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M (2009) Insulin receptor expression by human prostate cancers. Prostate 69(1):33–40
35. de Visser KE, Coussens LM (2006) The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 13:118–137
36. Gerber PA, Hippe A, Buhren BA, Muller A, Homey B (2009) Chemokines in tumor-associated angiogenesis. Biol Chem 390(12):1213–1223
37. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899
38. Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16(1):38–52
39. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1):24–37
40. Rosenkilde MM, Schwartz TW (2004) The chemokine system—a major regulator of angiogenesis in health and disease. Apmis 112(7–8):481–495
41. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7(4):256–269
42. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172(5 Pt 2):S6–S11 discussion S11–12
43. Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E (2000) Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 37(4):404–412
44. Klink JC, Banez LL, Gerber L, Lark A, Vollmer RT, Freedland SJ (2013) Intratumoral inflammation is associated with more aggressive prostate cancer. World J Urol 31(6):1497–1503
45. Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, Babaian RJ, Troncoso P (2005) Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11(19 Pt 1):6889–6894
46. Joshu CE, Mondul AM, Menke A, Meinhold C, Han M, Humphreys EB, Freedland SJ, Walsh PC, Platz EA (2011) Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prev Res 4(4):544–551
47. Diabetes Prevention Program Research Group (2012) Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care 35(4):731–737
48. Malin SK, Kashyap SR (2014) Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes 21(5):323–329